Episode Details
Back to EpisodesCOVID-19 clinical update #92 with Dr. Daniel Griffin
Episode 840
Published 4 years, 1 month ago
Description
In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long COVID following infection in previously vaccinated individuals.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Risk associated with Omicron (medRxiv)
- Expansion of monoclonal EUA (FDA)
- Neutralization of Omicron by sera (medRxiv)
- Third dose sera neutralize Omicron (Pfizer)
- Monoclonals authorized for PreP (FDA)
- Patient outcomes after monoclonals (Open Forum Inf Dis)
- Subcutaneous or intramuscular monoclonals (medRxiv)
- WHO does not recommend convalescent serum (WHO)
- Immunomodulation and thromboembolic risk (J Clin Med)
- Long COVID after infection of vaccinated (medRxiv)
- Letters read on TWiV 840
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv